Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 1 of 1 for:    Amitriptyline in the Prevention of Childhood Migraine
Previous Study | Return to List | Next Study

The Childhood and Adolescent Migraine Prevention Study (CHAMP)

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2014 by Children's Hospital Medical Center, Cincinnati
Information provided by (Responsible Party):
Children's Hospital Medical Center, Cincinnati Identifier:
First received: December 16, 2011
Last updated: November 10, 2014
Last verified: November 2014

The purpose of this research study is to test two medicines for migraine prevention in children and adolescents.

Condition Intervention Phase
Migraine Disorders
Drug: Amitriptyline
Drug: Topiramate
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Amitriptyline and Topiramate in the Prevention of Childhood Migraine

Resource links provided by NLM:

Further study details as provided by Children's Hospital Medical Center, Cincinnati:

Primary Outcome Measures:
  • Reduction in Migraine Frequency (amitriptyline and topiramate) [ Time Frame: 4 week baseline period to last 4 weeks of the 24-week trial ] [ Designated as safety issue: No ]
    To test if amitriptyline and topiramate are superior to placebo in reducing migraine frequency, as defined by the percentage of subjects with a 50% reduction in the number of migraine days per month, in children and adolescents ages 8-17.

Secondary Outcome Measures:
  • Reduction in absolute migraine disability score on PedMIDAS [ Time Frame: 4 week baseline period to last 4 weeks of the 24-week trial ] [ Designated as safety issue: No ]
    To determine if amitriptyline and/or topiramate will result in a decrease in absolute migraine disability score (measured by PedMIDAS).

  • Safety and tolerability of amitriptyline and topiramate [ Time Frame: 4 week baseline period to last 4 weeks of the 24-week trial ] [ Designated as safety issue: Yes ]

    To determine if amitriptyline and topiramate are well tolerated, and safe for participants and their care givers.

    Tolerability will be measured by a determination of the number of participants who are able to achieve the planned maximum dosage of the active study drugs without enduring dosage limiting side effects.

    Safety will be measured by the quantitative review of adverse events for all three arms of the study in comparison with placebo and the adverse events profiles reported in the package inserts for the study drugs.

  • Occurrence of treatment-emergent serious adverse events [ Time Frame: 4 week baseline period to last 4 weeks of the 24-week trial ] [ Designated as safety issue: Yes ]
    To determine if amitriptyline or topiramate differ from placebo on the occurrence of treatment-emergent serious adverse events.

  • Reduction in absolute migraine frequency days [ Time Frame: 4 week baseline period to last 4 weeks of the 24-week trial ] [ Designated as safety issue: No ]
    To determine if amitriptyline and/or topiramate will result in a decrease in absolute migraine frequency days.

Estimated Enrollment: 675
Study Start Date: June 2012
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Amitriptyline Drug: Amitriptyline
Amitriptyline will be administered twice daily at home during the 8-week titration period. The morning dose is a placebo pill. Dosing of amitriptyline will be weight-based.
Active Comparator: Topiramate Drug: Topiramate
Topiramate will be administered twice daily at home during the 8-week titration period. Dosing of topiramate will be weight-based.
Placebo Comparator: Placebo Drug: Placebo
Placebo will be administered twice daily at home during the 8-week titration period.

Detailed Description:

The purpose of this research study is to test two medicines for migraine prevention in children and adolescents. The investigators want to see if amitriptyline and/or topiramate are better than placebo (sugar pill) in reducing headache frequency in children and adolescents ages 8 to 17 with migraines. At this time, there are no FDA approved medicines approved in the US for the prevention treatment of migraine headaches in children and adolescents.


Ages Eligible for Study:   8 Years to 17 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Migraine with or without aura (International Classification of Headache Disorders, 2nd Edition (ICHD-II) or chronic migraine (ICHD-II revised)
  • Migraine frequency based upon prospective headache diary of 28 days must be ≥ 4. Migraine frequency defined as any migraine during one day in the 28 day baseline period (1)
  • PedMIDAS Disability Score > 10, indicating at least mild disruption in daily activities and < 140, indicating extreme disability that may require more comprehensive, multi-component therapy
  • Females or males 8-17 years, inclusive

    1. Migraine frequency is defined as the period from the onset to the stop time of painful migraine symptoms not to exceed 24 hours with the clock starting at midnight. If painful symptoms last longer than 24 hours, this is considered a new and distinct migraine headache. If painful symptoms recur within 24 hours of initial onset, this is considered part of the initial migraine episode and would be counted as one migraine.

Exclusion Criteria:

  • Continuous migraine defined as an unrelenting headache for a 28 day period
  • Weight less than 30 kg or greater than 120 kg
  • Unwilling to avoid taking non-specific acute medication such as NSAIDS (e.g., ibuprofen), more than 3 times per week, or migraine specific acute medications such as triptans more than 6 times per month
  • Currently taking other prophylactic anti-migraine medication within a period equivalent to 2 weeks of that medication before entering the screening phase
  • Subjects who have previously failed an adequate trial of AMI or TPM for prophylaxis of at least 3 months duration at doses recommended for migraine relief because of lack of efficacy or adverse events(2)
  • Current use of disallowed medications/products: opioids, antipsychotics, antimanics, barbiturates, benzodiazepines, muscle relaxants, sedatives, tramadol, nutraceuticals, SSRIs, or SSNRIs
  • Known history of allergic reaction or anaphylaxis to AMI or TPM
  • Abnormal findings on ECG at baseline, particularly lengthening of the QT interval greater than or equal to 450 msec
  • Subject is pregnant or has a positive pregnancy test
  • Subject is sexually active and not using a medically acceptable form of contraception
  • Diagnosis of epilepsy or other neurological diseases
  • History of kidney stones
  • Inability to swallow pills after using behavioral techniques if indicated between screening visit and baseline visit(3)
  • Present psychiatric disease as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM IV) (e.g. psychosis, bipolar disorder, major depression, generalized anxiety disorder), alcohol or drug dependence, or documented developmental delays or impairments (e.g., autism, cerebral palsy, or mental retardation) that, in the opinion of the site investigator, would interfere with adherence to study requirements or safe participation in the trial
  • Any and all other diagnoses or conditions which in the opinion of the site investigator, that would prevent the patient from being a suitable candidate for the study or interfere with the medical care needs of the study subject

    (2)"Previously failed an adequate trial of AMI or TPM" is defined as: dosage of 1mg/kg/day of AMI or 2 mg/kg/day of TPM; trial of at least 3 months duration; efficacy of having at least a 50% decrease in migraine frequency in response to drug therapy; or unable to tolerate taking the medication due to treatment-related side effects.

    (3)Subjects who cannot swallow pills at the time of the screening visit will be given a training session using behavioral techniques. Upon return for baseline visit, if the subject continues to be unable to swallow pills, the subject will be excluded from the study.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01581281

Contact: Leigh Ann Chamberlin, RD, MEd 513-636-9739
Contact: Leslie Korbee, BS, SI(ASCP) 513-636-6272

  Hide Study Locations
United States, Arizona
Phoenix Children's Medical Group Recruiting
Phoenix, Arizona, United States, 85016
Contact: Sajitha Puthalath    602-933-5003   
Principal Investigator: Marcy Yonker, MD         
United States, California
University of California-San Francisco Headache Center Recruiting
San Francisco, California, United States, 94115
Contact: Laura Dapkus    415-885-7832   
Principal Investigator: Amy Gelfand, MD         
Stanford Hospital and Clinics Recruiting
Stanford, California, United States, 94305
Contact: Pat Barrodale    650-721-2830   
Principal Investigator: Sheena Aurora, MD         
United States, Colorado
Children's Hospital Colorado Recruiting
Aurora, Colorado, United States, 80045
Contact: Megan Brocato    720-777-8864   
Principal Investigator: Sita Kedia, MD         
Colorado Springs Neurological Associates Active, not recruiting
Colorado Springs, Colorado, United States, 80907
United States, District of Columbia
Children's National Medical Center Recruiting
Washington DC, District of Columbia, United States, 20010
Contact: Tekolla Belaineh    202-476-2635   
Principal Investigator: Marc DiSabella, MD         
United States, Florida
Premiere Research Institute Recruiting
West Palm Beach, Florida, United States, 33407
Contact: Ashley Poulette    561-845-0500    ASHPRIRESEARCH@AOL.COM   
Principal Investigator: Paul Winner, DO         
United States, Georgia
Atlanta Headache Specialists Recruiting
Atlanta, Georgia, United States, 30342
Contact: Leslie Lopp    678-705-7341   
Principal Investigator: Frank Berenson, MD         
United States, Indiana
Josephson Wallack Munshower Neurology Research Recruiting
Indianapolis, Indiana, United States, 46237
Contact: Kristi Mann    317-806-6965   
Principal Investigator: Keith Ridel, MD         
United States, Kansas
Children's Mercy Hospital Recruiting
Kansas City, Kansas, United States, 66160
Contact: Gloria Womelduff    816-234-3492   
Principal Investigator: Jennifer Bickel, MD         
United States, Kentucky
University of Louisville Health Sciences Center Recruiting
Louisville, Kentucky, United States, 40292
Contact: Debra Brodfuehrer    502-813-6577   
Principal Investigator: Michael K Sowell, MD         
United States, Maryland
University of Maryland School of Medicine Completed
Baltimore, Maryland, United States, 21201
United States, Massachusetts
Children's Hospital of Boston Recruiting
Waltham, Massachusetts, United States, 02453
Contact: Alessandra Caruso    781-216-1975   
Principal Investigator: Alyssa LeBel, MD         
New England Regional Headache Center Recruiting
Worcester, Massachusetts, United States, 01605
Contact: Dianna Markley    508-890-5633   
Principal Investigator: Herbert G Markley, MD         
United States, Minnesota
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55905
Contact: Wendy Korn Peterson    507-284-3372   
Principal Investigator: Kenneth Mack, MD         
United States, Missouri
Saint Louis University Recruiting
St. Louis, Missouri, United States, 63104
Contact: Kimberly Stieglitz    314-268-2700 ext 3247   
Principal Investigator: Deepa Arun, MD         
United States, Nevada
University of Nevada Recruiting
Reno, Nevada, United States, 89502
Contact: Peggie Smith    775-982-6210   
Principal Investigator: Ivan Lopez, MD         
United States, New York
Dent Neurological Institute Recruiting
Amherst, New York, United States, 14226
Contact: Melissa Fuller    716-250-2016   
Principal Investigator: Jennifer McVige, MD         
Winthrop University Hospital Active, not recruiting
Mineola, New York, United States, 11501
The Headache Institute at Roosevelt Hospital Recruiting
New York, New York, United States, 10019
Contact: Iris Harris    212-523-2381    iharris@CHPNET.ORG   
Principal Investigator: Josh Cohen, MD         
Schenectady Neurological Constultants, PC Recruiting
Schenectady, New York, United States, 12308
Contact: Meriah Haig    518-381-9202   
Principal Investigator: Richard Simmons, MD         
United States, Ohio
Akron Children's Hospital Active, not recruiting
Akron, Ohio, United States, 44308
Cincinnati Children's Hospital Medical Center Recruiting
Cincinnati, Ohio, United States, 45229
Contact: Janelle Allen, MS    513-636-1840   
Principal Investigator: Marielle Kabbouche, MD         
The Children's Hospital, Cleveland Clinic Active, not recruiting
Cleveland, Ohio, United States, 44195
Nationwide Children's Hospital Recruiting
Columbus, Ohio, United States, 43205
Contact: Bonny Bowen    614-722-2689   
Principal Investigator: Anne Pakalnis, MD         
United States, Oklahoma
Oklahoma Health Sciences Recruiting
Oklahoma City, Oklahoma, United States, 73104
Contact: Chanel Seraphin    405-271-4658 ext 37182   
Principal Investigator: Deepti Chrusciel, MD         
United States, Pennsylvania
Children's Hospital of Philadelphia Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Janille Diaz    267-426-7104   
Principal Investigator: Christina Szperka, MD         
Preferred Clinical Research Recruiting
Pittsburgh, Pennsylvania, United States, 15236
Contact: Jill Lamance    412-650-6155   
Principal Investigator: Nathan Bennett, MD         
United States, Tennessee
LeBonheur Children's Hospital Recruiting
Memphis, Tennessee, United States, 38105
Contact: Catherine Horobetz    901-287-5330   
Principal Investigator: Diana Lebron, MD         
United States, Texas
Dallas Pediatric Neurology Associates Active, not recruiting
Dallas, Texas, United States, 75230
Scott and White Healthcare Recruiting
Temple, Texas, United States, 76508
Contact: Melissa Ainslie    254-724-5679   
Principal Investigator: Jose Aceves, MD         
United States, Utah
Primary Children's Medical Center Recruiting
Salt Lake City, Utah, United States, 84108
Contact: Rebbecca Perez    801-587-7759   
Principal Investigator: Lynne Kerr, MD         
United States, Virginia
Eastern Virginia Medical School Recruiting
Norfolk, Virginia, United States, 23510
Contact: Erika Paradiso    757-668-7732   
Principal Investigator: Matthew Frank, MD         
United States, Washington
Seattle Children's Hospital Recruiting
Seattle, Washington, United States, 98105
Contact: Cortney Greeley    206-987-2461   
Principal Investigator: Heidi Blume, MD         
United States, Wisconsin
Marshfield Clinic Recruiting
Marshfield, Wisconsin, United States, 54449
Contact: Pamela Mundt    715-389-3748   
Principal Investigator: Hemma Murali, MD         
Sponsors and Collaborators
Children's Hospital Medical Center, Cincinnati
Principal Investigator: Scott W. Powers, PhD Children's Hospital Medical Center, Cincinnati
Principal Investigator: Andrew D. Hershey, MD, PhD Children's Hospital Medical Center, Cincinnati
Principal Investigator: Christopher S. Coffey, PhD The University of Iowa
  More Information

No publications provided by Children's Hospital Medical Center, Cincinnati

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Children's Hospital Medical Center, Cincinnati Identifier: NCT01581281     History of Changes
Other Study ID Numbers: CIN-001, 1U01NS076788-01
Study First Received: December 16, 2011
Last Updated: November 10, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Children's Hospital Medical Center, Cincinnati:

Additional relevant MeSH terms:
Migraine Disorders
Amitriptyline, perphenazine drug combination
Brain Diseases
Central Nervous System Diseases
Headache Disorders
Headache Disorders, Primary
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Adrenergic Agents
Adrenergic Uptake Inhibitors
Analgesics, Non-Narcotic
Anti-Obesity Agents
Antidepressive Agents
Antidepressive Agents, Tricyclic
Antipsychotic Agents
Central Nervous System Agents
Central Nervous System Depressants
Molecular Mechanisms of Pharmacological Action
Neuroprotective Agents
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Peripheral Nervous System Agents
Pharmacologic Actions processed this record on November 25, 2014